Home

Advancing scientific knowledge

Our Company

Driven by our dedication to improving outcomes in difficult-to-treat cancers, we are leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology.

Our Science

Advancing antibody drug conjugates with a novel class of PBD dimers

Our Pipeline

A robust pipeline of investigational ADCs for the treatment of hematological cancers and solid tumors


Our Trials

Take a closer look at the LOTIS study designs


Recent Data Presentations

Explore the latest research from our scientists

Relationship between exposure and safety/efficacy of loncastuximab tesirine (Lonca) in B-cell non-Hodgkin lymphoma (B-NHL)

Hess B, Ai W, Townsend W, et al.

Integrated population modeling of loncastuximab tesirine (Lonca) exposure in B-cell non-Hodgkin lymphoma (B-NHL)

Solh M, Alderuccio JP, Stathis A, et al.

Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/
Refractory Diffuse Large B-Cell Lymphoma

Caimi PF, Ai W, Alderuccio JP, et al.

Safety and Antitumor Activity Study Evaluating Loncastuximab Tesirine and Rituximab Versus Immunochemotherapy in Diffuse Large B-Cell Lymphoma

Linhares Y, Gandhi M, Chung M, et al.

Interim Results of Loncastuximab Tesirine Combined With Ibrutinib in Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma (LOTIS-3)

Depaus J, Wagner-Johnston ND, Zinzani PL, et al.

Symptoms, Health-Related Quality of Life, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Spira AI, Chen L, Zhou X, et al.

Characteristics and Treatment Patterns of Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Received ≥3 Lines of Therapies

Xie J, Wu A, Liao L, et al.

Analysis of ADCT-602 Pre-Clinical Activity in B-Cell Lymphoma Models and Identification of Potential Biomarkers for Its Activity

Gaudio E, Tarantelli C, Cascione L, et al.

Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients With Relapsed or Refractory Hodgkin Lymphoma

Herrera AF, Carlo-Stella C, Collins GP, et al.

Combination of Camidanlumab Tesirine, a CD25-Targeted ADC, With Gemcitabine Elicits Synergistic Anti-Tumor Activity in Preclinical Tumor Models

Jabeen A, Huang S, Hartley JA, et al.

Pharmacokinetic and Pharmacodynamic Correlates From the Phase 1 Study of Camidanlumab Tesirine (Cami) in Patients With Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma

Boni J, Havenith K, Hamadani M, et al.



MedConnect

Real-time answers to your pressing questions

Connect live with Medical Affairs

Our Company

Driven by our dedication to improving outcomes in difficult-to-treat cancers, we are leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology.Watch a short video to learn more about our company (2:05)

Read and download our brochure

Our Science

Advancing antibody drug conjugates with a novel class of PBD dimersADC Therapeutics’ proprietary ADCs are highly targeted drug constructs that combine monoclonal antibodies specific to surface tumor targets with a novel class of highly potent PBD-dimer toxins.PBD dimers do not distort the DNA structure, which makes them invisible to repair mechanisms and allows the cross-links to persist within the DNA. Unlike earlier generation PBD chemistry, ADC Therapeutics’ proprietary PBD dimers are not a substrate for multi-drug resistance proteins—even in hard-to-treat tumors.Our PBD-dimer technology: A novel approach to hematologic cancers and solid tumors

  • 1The antigen-targeted antibody binds to a specific tumor cell surface antigen and internalizes the drug conjugate
  • 2The potent PBD dimer is released inside the cell, where it then creates a covalent cross-link between the strands of the DNA double helix
  • 3Because these cross links do not trigger DNA repair, they are invisible to repair mechanisms and can covertly persist to interrupt cell division and cause tumor cell death

Watch an MOA video about our first approved ADC, loncastuximab tesirine-lpyl (2:32)

Our Pipeline

A robust pipeline of investigational ADCs for the treatment of hematological cancers and solid tumorsADCT has multiple PBD-based ADCs in ongoing clinical trials and numerous preclinical ADCs in development.Some of the agents represented in this pipeline chart are investigational. Efficacy and safety have not yet been established.

Expand each compound to learn more.

LONCASTUXIMAB TESIRINE-lpyl

Loncastuximab tesirine-lpyl is an ADC composed of a humanized monoclonal antibody that binds to human CD19 and is conjugated through a linker to a PBD–dimer toxin. CD19 is a clinically validated target for the treatment of B-cell malignancies.

CAMIDANLUMAB TESIRINE

Camidanlumab tesirine, ADCT’s second lead candidate, has demonstrated significant clinical activity in heavily pretreated patients with Hodgkin lymphoma. Based on its mechanism targeting CD25/regulatory T cells, camidanlumab tesirine is also demonstrating potential in the treatment of solid tumors.

adct-602

ADCT-602 is an ADC composed of a monoclonal antibody that binds to CD22 conjugated to a PBD-dimer toxin. CD22 is highly expressed on most malignant B-cells, including expression in more than 90% of patients with B-cell acute lymphoblastic leukemia (ALL). ADCT-602 is being evaluated in a phase I/II clinical trial in patients with relapsed or refractory B-cell ALL.

adct-601

ADCT-601 is an ADC composed of a humanized monoclonal antibody that binds to human AXL (licensed from BerGenBio), conjugated using Glycoconnect™ technology (licensed from Synaffix BV) to a linker with a PBD-dimer toxin. AXL is highly overexpressed in many solid tumors and hematological malignancies. ADCT-601 is being evaluated in a phase 1 clinical trial in patients with selected advanced solid tumors.
adct-901

ADCT-901 is an ADC composed of a humanized monoclonal antibody (3A4) directed against human KAAG1 and conjugated through a cathepsin-cleavable linker to SG3199, a PBD–dimer cytotoxin. KAAG1 has high expression in tumors with high unmet medical need, while its expression on healthy tissue is very restricted. ADCT-901 is being developed for the treatment of advanced solid tumors with high unmet medical needs, including platinum resistant ovarian cancer and triple negative breast cancer.
adct-701

ADCT-701 is an ADC composed of a humanized monoclonal antibody (HuBa-1-3D) directed against human DLK-1 and conjugated through a cathepsin-cleavable linker to SG3199, a PBD-dimer cytotoxin. DLK-1 is an attractive novel tumor target for ADC development as it is expressed in adults in several tumors. ADCT-701 is being developed for the treatment of advanced solid tumors with high unmet medical needs, neuroblastoma, hepatocellular carcinoma, and small cell lung cancer.

Learn more about our pipeline Watch a video tour of the LOTIS Clinical Development Program (3:00)

Read and download the
LOTIS brochure

Our Trials

Take a closer look at the LOTIS study designs

Recent Data Presentations

Explore the latest research from our scientists

Relationship between exposure and safety/efficacy of loncastuximab tesirine (Lonca) in B-cell non-Hodgkin lymphoma (B-NHL)Hess B, Ai W, Townsend W, et al.View Abstract
Integrated population modeling of loncastuximab tesirine (Lonca) exposure in B-cell non-Hodgkin lymphoma (B-NHL)Solh M, Alderuccio JP, Stathis A, et al.View Abstract
Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell LymphomaCaimi PF, Ai W, Alderuccio JP, et al.View Abstract
Safety and Antitumor Activity Study Evaluating Loncastuximab Tesirine and Rituximab Versus Immunochemotherapy in Diffuse Large B-Cell LymphomaLinhares Y, Gandhi M, Chung M, et al.View Abstract
Interim Results of Loncastuximab Tesirine Combined With Ibrutinib in Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma (LOTIS-3)Depaus J, Wagner-Johnston ND, Zinzani PL, et al.View Abstract
Symptoms, Health-Related Quality of Life, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaSpira AI, Chen L, Zhou X, et al.View Abstract
Characteristics and Treatment Patterns of Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Received ≥3 Lines of TherapiesXie J, Wu A, Liao L, et al.View Abstract
Analysis of ADCT-602 Pre-Clinical Activity in B-Cell Lymphoma Models and Identification of Potential Biomarkers for Its ActivityGaudio E, Tarantelli C, Cascione L, et al.View Abstract
Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients With Relapsed or Refractory Hodgkin LymphomaHerrera AF, Carlo-Stella C, Collins GP, et al.View Abstract
Combination of Camidanlumab Tesirine, a CD25-Targeted ADC, With Gemcitabine Elicits Synergistic Anti-Tumor Activity in Preclinical Tumor ModelsJabeen A, Huang S, Hartley JA, et al.View Abstract
Pharmacokinetic and Pharmacodynamic Correlates From the Phase 1 Study of Camidanlumab Tesirine (Cami) in Patients With Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin LymphomaBoni J, Havenith K, Hamadani M, et al.View Abstract